NovoCure NVCR United States — Net revenues
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by NovoCure in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about NovoCure's united states — net revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is NovoCure's united states — net revenues?
- NovoCure (NVCR) reported united states — net revenues of $95.96M in Q1 2026.
- How has NovoCure's united states — net revenues changed year-over-year?
- NovoCure's united states — net revenues increased by 3.0% year-over-year, from $93.15M to $95.96M.
- What is the long-term trend for NovoCure's united states — net revenues?
- Over 4 years (2021 to 2025), NovoCure's united states — net revenues has grown at a 2.2% compound annual growth rate (CAGR), from $353.11M to $385.63M.
- What does united states — net revenues mean?
- This metric represents the total revenue generated from the sale of medical devices and associated services within the United States geographic market after accounting for returns, discounts, and allowances. It serves as a primary indicator of the company's commercial penetration and market demand for its therapeutic technologies within this specific region. Tracking this figure helps investors evaluate the effectiveness of regional sales strategies and the adoption rate of the company's product portfolio.